Cerebral Palsy (CP), as the most common motor developmental disorder in childhood, has a global prevalence rate of up to 3‰. The prevalence rate among children aged 0-6 in China is 1.8-4‰, with an annual increase of 46,000 new cases. This motor disorder syndrome caused by non-progressive brain injury was traditionally considered incurable, and patients face lifelong limitations in motor function, secondary musculoskeletal deformities, and social participation barriers. However, with the cross-integration of neuroscience, regenerative medicine, and intelligent technologies, the treatment of cerebral palsy is undergoing a revolutionary transformation from "symptom management" to "functional remodeling".
The latest research in 2025 has confirmed that the etiological understanding of cerebral palsy has undergone significant updates. A study by the Slovenian National Cerebral Palsy Registry, through whole-exome sequencing of 136 children, found that approximately 6.6% of cases had pathogenic variants in genes such as ATL1 and CTNNB1, and some of these children even had normal brain MRI. This discovery has shaken the traditional concept that "cerebral palsy is purely an acquired injury" and provided a new direction for genetic counseling and targeted therapy. Meanwhile, the establishment of a multimodal treatment system has significantly improved the survival rate of high-risk children, and the treatment goal has shifted from simply prolonging survival to comprehensively improving the quality of life.
• Functional Selective Posterior Rhizotomy (FSPR): The FSPR surgery performed by Shenzhen Overseas Chinese Hospital in 2025 selectively blocks La fiber afferent signals through intraoperative electrophysiological monitoring, enabling 90% of children to have muscle tone restored to the normal range and improving postoperative dynamic balance ability by 80%. This technology is particularly suitable for spastic children in the 3-7-year-old golden window period. Even older patients can improve their self-care ability through the "surgery-rehabilitation integration" program.
• Surface Electromyography Synergy Technology-Assisted Surgery: The technology developed by the team of Zhou Huixia from the PLA General Hospital collects real-time lower limb muscle electrical activity through 64-channel high-density sEMG and constructs a muscle synergy defect model combined with AI algorithms. Clinical data in 2024 showed that the postoperative independent walking rate of children guided by this technology increased by 40%, the functional grade jumped from grade III to grade I, and the complication rate was controlled below 5%.
• Selective Percutaneous Myofascial Lengthening (SPML): A controlled trial conducted by the University of Athens in Greece confirmed that after SPML combined with 9 months of functional physical therapy, the scores of children in the D and E dimensions of the Gross Motor Function Measure (GMFM) significantly improved (p<0.05), and the functional mobility in 5m, 50m, and 500m distances measured by the Functional Mobility Scale (FMS) all improved. This minimally invasive surgical method avoids extensive dissection of traditional open surgery and accelerates the postoperative rehabilitation process.
The hand surgery team of Beijing Jishuitan Hospital innovatively applied peripheral nerve surgery technology to the treatment of central spastic paralysis. At the 2025 Sitges International Conference in Spain, Professor Wang Shufeng demonstrated T1 nerve root 切断术 and S2 nerve root selective 切断术，which accurately relieved upper limb flexor finger spasm and lower limb equinovarus deformity through intraoperative neuroelectrophysiological positioning. This technology breaks through the limitations of traditional orthopedic surgery, achieves spasm control while preserving muscle proprioception, and provides a new solution for mixed cerebral palsy.
Table 1: Comparison of Clinical Efficacy of Cerebral Palsy Surgical Technologies (2025)
Technology Type | Applicable Population | Core Advantages | Functional Improvement Rate | Complication Rate |
FSPR | 3-7-year-old spastic type | Comprehensive adjustment of muscle tone | 90% | 8-12% |
Electromyography Navigation Surgery | GMFCS II-IV | Individualized muscle strength balance | 85% | <5% |
SPML | School-age children | Minimally invasive, rapid rehabilitation | 78% | 3-5% |
Peripheral Nerve Regulation | Mixed type with severe spasm | Preservation of proprioception | 82% | 6-8% |
Stem cell therapy has become a new hope for cerebral palsy treatment through multi-target nerve repair mechanisms:
• Neural Differentiation and Replacement: Transplanted neural stem cells can migrate to the injury site and differentiate into functional neurons.
• Nutrient Factor Secretion: Mesenchymal stem cells secrete more than 20 kinds of neurotrophic factors such as BDNF and GDNF.
• Immunomodulation: Inhibits excessive activation of microglia and reduces neuroinflammation.
• Angiogenesis: Promotes microvascular reconstruction in the injury area and improves local microcirculation.
A randomized controlled trial published in "Stem Cell Research & Therapy" in 2023 first confirmed the safety and effectiveness of intranasal administration of neural stem cell patches. 15 children who received treatment showed significant improvement in standing and walking ability within 1 month, with a 36% improvement in GMFM-88 scores. More surprisingly, there was a delayed improvement in hand fine motor skills after 24 months. A 2025 meta-analysis of 1292 patients further showed that umbilical cord mesenchymal stem cell intrathecal injection significantly improved GMFM scores at 3 months (effect size 0.97-1.05), and the effect lasted for more than 12 months. DTI imaging confirmed that the integrity of white matter fiber bundles in the treatment group was significantly improved, providing a structural basis for functional recovery.
In 2025, Zhongshan Hospital Affiliated to Fudan University achieved the "cerebrospinal interface" technology, which for the first time in the world realized the reconstruction of walking function in paraplegic patients through minimally invasive implantation. The technical breakthrough includes three major innovations:
1. Signal Acquisition: Implant electrodes in the motor cortex to capture motor intention signals.
2. Intelligent Decoding: AI algorithms convert neural signals into stimulation commands.
3. Spinal Cord Regulation: Epidural electrodes activate the lumbosacral motor center, bypassing the injury area to establish a "nerve bypass".
The first patient, Mr. Lin, achieved autonomous brain-controlled lower limb movement on the 3rd day after surgery and could walk with suspension assistance on the 49th day. The revolutionary significance of this technology lies in breaking the traditional perception that "complete spinal cord injury is irrecoverable", bringing hope to children with cerebral palsy complicated with spinal cord lesions.
At the same time, the Epilcure closed-loop neuromodulation system developed by Jialiang Medical adopts a full skull implantation design, which significantly reduces the frequency of epileptic seizures through real-time EEG monitoring and responsive stimulation. In 2025, this technology has been extended to the field of cerebral palsy spasm control, and its built-in wireless charging system and artificial intelligence decoding chip provide a safety guarantee for long-term implantation.
Table 2: Comparison of Global Neural Interface Technologies (2025)
Technology System | Research Institution | Core Technology | Indication Expansion | Clinical Application |
Cerebrospinal Interface | Fudan University | Brain-spinal cord closed-loop | Paraplegia, cerebral palsy spasm | 4 successful clinical cases |
Epilcure System | Jialiang Medical | Wireless charging full skull implantation | Epilepsy, spasm control | Hundreds of implantations |
Neuralink N1 | Neuralink | Flexible electrodes, R1 robot | Tetraplegia, ALS | Clinical trials in the United States and Canada |
Closed-loop DBS | Xuanwu Hospital | β signal adaptive stimulation | Parkinson's disease, dystonia | Multicenter research |
The MyoStep flexible exoskeleton developed by the University of Houston in the United States in 2025 represents a revolutionary breakthrough in rehabilitation equipment:
• Bionic Drive System: A 0.2mm thick shape memory alloy layer simulates muscle contraction to provide natural ankle thrust.
• Multi-Joint Coordination Algorithm: Hip-knee-ankle linkage control reduces gait energy consumption by 22%.
• Intelligent Safety Protection: Embedded temperature sensors monitor skin temperature in real-time, and automatically power off when overheating.
• Daily Integration Design: Sensor fabrics are seamlessly integrated into regular clothing, supporting all-day wear.
The DAS-AFO adjustable stiffness ankle-foot orthosis synchronously developed by Chinese scientists innovatively adopts a leaf spring structure, realizing scene-adaptive switching between low stiffness to improve propulsion during running (ankle power ↑24%) and high stiffness to enhance stability during standing (center of gravity swing ↓16%), completely changing the static support limitation of traditional orthoses.
A randomized controlled trial by the Indian Institute of Science and Innovation confirmed that VR-based motion game intervention can increase the training compliance of children with cerebral palsy to 84.4-100%. After 3 months of training, 8 children with hemiplegia showed significant improvements in fine motor skills, hand-eye coordination, and visual perception in the BOT-2 motor ability test.
The "AI Rehabilitation Therapist" system deployed in Nantong Second Hospital, China, shortens the traditional 30-minute rehabilitation assessment to within 5 minutes through non-contact posture recognition technology. The system uses deep learning algorithms to analyze the center of gravity shift and joint torque during patient movement, automatically generates personalized training plans including early warning of abnormal movement patterns, and improves the assessment efficiency by 6 times.
The Jiangsu "Tuomiao Plan" innovatively constructed a government-family-society (4:3:3) cost-sharing mechanism and trained parents of children as certified rehabilitation therapists, solving the dual dilemmas of shortage of rehabilitation resources and family economic burden. This model has been included in the Asia-Pacific Cerebral Palsy Alliance's "2030 White Paper on Eliminating the Rehabilitation Gap" and has completed a pilot promotion for 20,000 children in Vietnam.
To address the special challenges in low-income areas, India launched the "Mobile SEMLS Unit" integrating portable gait analyzers and basic surgical equipment, enabling complex surgeries to be carried out in county-level hospitals. The African Solar-Powered Rehabilitation Vehicle Project maintains the operation of rehabilitation equipment in off-grid areas through photovoltaic power supply systems, benefiting villages in sub-Saharan Africa.
• Gene-Cell Synergistic Therapy: CRISPR-Cas9 gene-corrected stem cells for genetic subtypes (such as CTNNB1 mutations) are expected to enter clinical trials in 2026.
• Home-Based Brain-Computer Interface: Fudan University and Jialiang Medical are cooperating to develop a low-cost non-implantable EEG-exoskeleton system, aiming to control the equipment price to 1/5 of the current system.
• Biohybrid Repair: Carbon nanotube-reinforced nerve scaffold materials can conduct electrical signals and load stem cells at the same time. Animal experiments show that the recovery speed of motor function is increased by 2.3 times.
Despite significant technological progress, cerebral palsy treatment still faces multiple challenges:
• Nerve Regeneration Efficiency: The neural differentiation rate of existing stem cell therapies is less than 15%, and magnetic guidance targeting technology needs to be combined to improve colonization in the lesion area.
• Technology Inclusiveness Barriers: The unit price of flexible exoskeletons exceeds $20,000, and the coverage rate in developing countries is less than 5%.
• Long-Term Safety: Long-term biocompatibility data of cerebrospinal interface implants are still lacking, and the first patient has only been followed up for 18 months.
In response to these challenges, a global collaborative network is taking shape. The European Brain Project is building the first human brain motor neural network map to provide navigation for precise regulation; Japan is promoting ultra-early intervention within 72 hours after the birth of high-risk infants; and China's "Belt and Road" Cerebral Palsy Prevention and Treatment Alliance is committed to technology transfer, planning to establish demonstration centers in 20 countries by 2030.
From Marchand's pathological description of cerebral palsy to today's neural interfaces and stem cell regeneration, humanity's journey against this disease has witnessed amazing leaps in medicine. Cerebral palsy treatment in 2025 is no longer satisfied with symptom relief, but focuses on the systematic reconstruction of neural circuits and the complete recovery of social functions. When 10-year-old Kuang Kuang chases virtual dolphins in VR training, when 46-year-old Xu Liang walks by driving an exoskeleton through an EEG cap, and when stem cell-awakened neurons re-light signals in the network - we see not only the victory of technology but also the transcendence of life over constraints.
As a rehabilitation therapist in the Jiangsu "Tuomiao Plan" wrote in his log: "When a child once declared 'lifelong speechless' recites 'Min Nong', and when a curled finger holds a paintbrush for the first time, we finally understand that the ultimate mission of medicine is not to fight against defects, but to awaken those frozen possibilities." On this road from millimeter-level surgery to molecular-level repair, the deep integration of Chinese wisdom and international innovation is gradually removing the label of "incurable" and writing a chapter of rebirth for 7.7 million cerebral palsy patients worldwide.
EN
CN